The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisai and Biogen’s Leqembi.

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi ... And remember that APOE e4 gene? Having two copies also boosts the risk of ARIA. So before people start ...

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla ... And remember that APOE e4 gene? Having two copies also boosts the risk of ARIA. So before ...

Eisai has filed for approval of its Alzheimer’s disease therapy Leqembi in South Korea ... that seem to be more common in patients with ApoE ε4 mutations and among those taking anticoagulants ...

Due to an even larger risk of ARIA-E, both drugs are used with greater caution, if at all, for people with two copies of the APOE-4 gene, which indicates a genetic disposition for Alzheimer’s.

A second, somewhat less controversial, anti-amyloid agent gained approval in January 2023: lecanemab (Leqembi ... serious ARIA subsequently died, two of whom were heterozygous APOE carriers ...